JPWO2022066911A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022066911A5
JPWO2022066911A5 JP2023518378A JP2023518378A JPWO2022066911A5 JP WO2022066911 A5 JPWO2022066911 A5 JP WO2022066911A5 JP 2023518378 A JP2023518378 A JP 2023518378A JP 2023518378 A JP2023518378 A JP 2023518378A JP WO2022066911 A5 JPWO2022066911 A5 JP WO2022066911A5
Authority
JP
Japan
Prior art keywords
vector
aav
aav vector
seq
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542950A5 (https=
JP2023542950A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/051758 external-priority patent/WO2022066911A1/en
Publication of JP2023542950A publication Critical patent/JP2023542950A/ja
Publication of JP2023542950A5 publication Critical patent/JP2023542950A5/ja
Publication of JPWO2022066911A5 publication Critical patent/JPWO2022066911A5/ja
Pending legal-status Critical Current

Links

JP2023518378A 2020-09-23 2021-09-23 α-シヌクレインの凝集を阻害するための組成物及び方法 Pending JP2023542950A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063082208P 2020-09-23 2020-09-23
US63/082,208 2020-09-23
PCT/US2021/051758 WO2022066911A1 (en) 2020-09-23 2021-09-23 Compositions and methods for inhibiting alpha-synuclein aggregation

Publications (3)

Publication Number Publication Date
JP2023542950A JP2023542950A (ja) 2023-10-12
JP2023542950A5 JP2023542950A5 (https=) 2024-10-02
JPWO2022066911A5 true JPWO2022066911A5 (https=) 2024-10-02

Family

ID=80845817

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518378A Pending JP2023542950A (ja) 2020-09-23 2021-09-23 α-シヌクレインの凝集を阻害するための組成物及び方法

Country Status (7)

Country Link
US (1) US20240025953A1 (https=)
EP (1) EP4216978A4 (https=)
JP (1) JP2023542950A (https=)
CN (1) CN116457466A (https=)
AU (1) AU2021349261A1 (https=)
CA (1) CA3192936A1 (https=)
WO (1) WO2022066911A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116590342B (zh) * 2023-05-11 2026-04-03 普递瑞(上海)医药有限公司 一种aav载体及其应用
WO2024229777A1 (zh) * 2023-05-11 2024-11-14 深圳先进技术研究院 一种aav载体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680145A4 (en) * 2003-10-14 2007-05-23 Neurologix Res Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
EP2154969B1 (en) * 2007-05-16 2015-11-18 The Brigham and Women's Hospital, Inc. Treatment of synucleinopathies
JP2016503405A (ja) * 2012-11-05 2016-02-04 ジェンザイム・コーポレーション タンパク質症を処置するための組成物および方法
US20170184612A1 (en) * 2014-04-09 2017-06-29 The Trustees Of Columbia University In The City Of New York Use of leukocytes and novel biomarkers in the diagnosis, confirmation, and treatment of a neurological disorder
KR102423442B1 (ko) * 2015-12-11 2022-07-20 캘리포니아 인스티튜트 오브 테크놀로지 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
CA3029676A1 (en) * 2016-06-29 2018-01-04 The Regents Of The University Of California Structure-based peptide inhibitors of alpha-synuclein aggregation
WO2019036673A1 (en) * 2017-08-18 2019-02-21 The Medical College Of Wisconsin, Inc. THERAPY BASED ON SRCP1 FOR DISEASES ASSOCIATED WITH PROTEIN AGGREGATION
WO2019068854A1 (en) * 2017-10-06 2019-04-11 Ospedale San Raffaele S.R.L. GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS
CA3096293A1 (en) * 2018-04-27 2019-10-31 Rocket Pharmaceuticals, Ltd. Gene therapy for cns degeneration
CA3118692A1 (en) * 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases

Similar Documents

Publication Publication Date Title
JP2025078652A5 (https=)
JP2022033855A5 (https=)
IL299325B2 (en) Acid-alpha glucosidase variants and uses thereof
JP2019511570A5 (https=)
RU2018116076A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
US20040087028A1 (en) Ecdysone-inducible adeno-associated virus expression vectors
JP2009526067A5 (https=)
JP2021534814A5 (https=)
JPWO2020106916A5 (https=)
WO2019227219A1 (en) Adeno-associated viral vector-mediated gene therapy for treating fragile x-associated disorders
JPWO2021067448A5 (https=)
JP2023065516A5 (https=)
JP2023059858A5 (https=)
JP2025090820A5 (https=)
JP2021511020A5 (https=)
JP2020510433A5 (https=)
JPWO2019204593A5 (https=)
JPWO2022066911A5 (https=)
FI3177313T3 (fi) Telomeraasi-käänteistranskriptaasipohjaisia hoitoja sydäninfarktiin liittyvien tilojen hoitamiseksi
JP2020519251A5 (https=)
JPWO2021014428A5 (https=)
JPWO2022015715A5 (https=)
JPWO2023093905A5 (https=)
JPWO2022018171A5 (https=)
JPWO2020237130A5 (https=)